Alexion Pharmaceuticals Inc. (ALXN)

106.09
4.80 4.70
NASDAQ : Health Technology
Prev Close 101.34
Open 101.60
Day Low/High 101.50 / 105.13
52 Wk Low/High 92.56 / 141.86
Volume 1.76M
Avg Volume 2.38M
Exchange NASDAQ
Shares Outstanding 224.23M
Market Cap 22.25B
EPS 0.30
P/E Ratio 7.35
Div & Yield N.A. (N.A)
Here Are Several Promising Rare Disease Stocks

Here Are Several Promising Rare Disease Stocks

These small biotech concerns are undervalued.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of Tanisha Carino, Ph.

Alexion And Stealth Announce Agreement For Option To Co-Develop And Commercialize Late-Stage Therapy For Mitochondrial Diseases

Alexion And Stealth Announce Agreement For Option To Co-Develop And Commercialize Late-Stage Therapy For Mitochondrial Diseases

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Stealth BioTherapeutics Corp (NASDAQ:MITO) today announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases.

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

Alexion To Report Third Quarter 2019 Results On Wednesday, October 23, 2019

Alexion To Report Third Quarter 2019 Results On Wednesday, October 23, 2019

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019.

3 Biotech Plays That Would Work as Covered Calls

3 Biotech Plays That Would Work as Covered Calls

The SPDR S&P Biotech ETF, Alexion Pharmaceuticals and BioMarin Pharmaceuticals set up nicely for this options strategy.

Alexion Shares Slide After Departure of Chief Financial Officer

Alexion Shares Slide After Departure of Chief Financial Officer

Paul Clancy will step down later this year and be succeeded by chief strategy and business officer, Aradhana Sarin.

Alexion Announces CFO Succession

Alexion Announces CFO Succession

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans for the transition of Executive Vice President and Chief Financial Officer Paul Clancy later this year.

Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Alexion And BridgeBio Announce Japanese License Agreement For Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and BridgeBio Pharma, Inc.

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks

Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.

Alexion To Present At The 17th Annual Morgan Stanley Global Healthcare Conference

Alexion To Present At The 17th Annual Morgan Stanley Global Healthcare Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.

Alexion Announces Upcoming Data Presentations At 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Alexion Announces Upcoming Data Presentations At 35th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS ® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) have been accepted for presentation at the 35 th Congress of the...

Alexion To Present At The 14th Annual Citi Biotech Conference

Alexion To Present At The 14th Annual Citi Biotech Conference

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.

European Commission Approves SOLIRIS® (eculizumab) For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

European Commission Approves SOLIRIS® (eculizumab) For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission (EC) has approved the extension of the current marketing authorization of SOLIRIS ® (eculizumab) to include the treatment of neuromyelitis optica spectrum disorder...

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

Mizuho's Salim Syed says talk of possible tieup isn't far-fetched. Alexion and Amgen decline comment.

Amgen and Johnson & Johnson Get a Checkup

Jefferies raises its price target for AMGN and judgement day looms for JNJ; here's our take on the health of both companies.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: NYCB, RDY, VIAV Downgrades: ALXN, BGG, BTU, EOG, FFIC, GNE, HONE, IPG, KEX, LCUT, MAGS, MCFT, PCSB, UVE Initiations: ECOR Read on to get TheStreet Quant Ratings' detailed report:

Alexion Pharmaceuticals Takes Over #104 Spot From Eastman Chemical

Alexion Pharmaceuticals Takes Over #104 Spot From Eastman Chemical

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #104 spot from Eastman Chemical Co , according to ETF Channel.

Alexion Receives Positive CHMP Opinion For SOLIRIS® (eculizumab) For The Treatment Of NMOSD

Alexion Receives Positive CHMP Opinion For SOLIRIS® (eculizumab) For The Treatment Of NMOSD

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to extend the current marketing authorization of SOLIRIS ®...

Alexion Reports Second Quarter 2019 Results

Alexion Reports Second Quarter 2019 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2019.

Alexion To Report Second Quarter 2019 Results On Wednesday, July 24, 2019

Alexion To Report Second Quarter 2019 Results On Wednesday, July 24, 2019

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2019 before the US financial markets open on July 24, 2019.

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization From European Commission For Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

ULTOMIRIS® (ravulizumab) Receives Marketing Authorization From European Commission For Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has approved ULTOMIRIS ® (ravulizumab) — the first and only long-acting C5 complement inhibitor administered every eight weeks — for the treatment of adult patients...

SOLIRIS® Product Photo (Photo: Business Wire)

SOLIRIS® Product Photo (Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

TheStreet Quant Rating: C+ (Hold)